Mirna Therapeutics, which is developing microRNA replacement therapies for liver cancer, lowered the proposed deal size for its upcoming IPO on Wednesday. The Austin, TX-based company now plans to raise $44 million by offering 6 million shares at a price of $7. The company had previously filed to offer 5 million shares at a range of $13 to $15.
Mirna Therapeutics, which was founded in 2007, plans to list on the Nasdaq under the symbol MIRN. Mirna Therapeutics initially filed confidentially on 3/12/2014. Citi and Leerink Partners are the joint bookrunners on the deal.
